The Phase II SWOG 1609 (DART) trial (NCT02834013) is investigating dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors. Young Kwang Chae, MD, MPH, MBA, National Cancer Institute, Bethesda, MD, shares the first results of desmoid tumors. Sixteen evaluable patients with DT were analyzed, and the objective response rate (ORR) was 18.8%, with 3 patients showing partial responses and 3 patients with stable disease. The overall clinical benefit rate (CBR) was 62.5%. Adverse events included fatigue, nausea, hypothyroidism, diarrhea, and others. The study demonstrates promising efficacy and durable responses in DT, and further prospective studies are warranted to explore the potential of this combination therapy in this rare disease. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
